{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-001616","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.095171+00:00","generated_at":"2026-06-20T11:33:23.841121+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dyadic sells Alphazyme equity interest for ~$1.27M, retains sublicense rights","bullets":["Received approx. $1.27M from sale of Alphazyme equity interest.","Non-exclusive sublicense remains; Dyadic gets milestone/royalty payments on C1-expressed products.","Potential additional payments based on future sales of Alphazyme's existing products.","Alphazyme Sale Agreement executed January 18, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-001616","json":"https://secwatch.observer/filing/0001437749-23-001616.json","markdown":"https://secwatch.observer/filing/0001437749-23-001616.md","text":"https://secwatch.observer/filing/0001437749-23-001616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/0001437749-23-001616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/dyai20230116_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:33:23.841121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"584cf3ff575026e0a584523a002a10c6758d0b56","claim":"DYADIC INTERNATIONAL INC entered into Alphazyme Sale Agreement with Alphazyme, LLC valued at approximately US$1.27 million (effective 2023-01-18).","evidence_excerpt":"On January 18, 2023, Dyadic International, Inc. (“Dyadic” or the “Company”) entered into a Securities Purchase Agreement under which the Company agreed to sell its equity interest in Alphazyme, LLC (the \"Alphazyme Sale Agreement\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/0001437749-23-001616-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Alphazyme, LLC"},{"label":"Value","value":"approximately US$1.27 million"},{"label":"Effective","value":"2023-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}